Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › csDMARDs

csDMARDs

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of csDMARDs

3 trials tracked of csDMARDs: 3 in phase 3 or 4 and 3 with published results. The most-cited published study has 329 citations.

3Trials tracked
3Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 3 3
  1. Phase 3 Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment Completed · 329 cited
  2. Phase 3 A Study of Tocilizumab (RoActemra) in Tocilizumab-Naive Participants With Rheumatoid Arthritis and Inadequate Response to Non-Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) and/or Biologic Therapy Completed · 37 cited
  3. Phase 3 Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors Completed · 33 cited

Showing the 3 most-cited and recently-updated of 3 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Combination therapies with adalimumab, infliximab, tofacitinib, or upadacitinib increase serious infection risk in rheumatoid arthritis
Rheumatology Sys. Review
Combination therapies with adalimumab, infliximab, tofacitinib, or upadacitinib increase serious infection risk in rheumatoid arthritis New data shows infection risks for rheumatoid arthritis treatments
This meta-analysis of 55,749 patients with rheumatoid arthritis found that while b/tsDMARD monotherapy carries a similar risk of serious inf…
New research highlights how combining certain medications for rheumatoid arthritis can increase the risk of serious infections.
Jul 18, 2026
Hand-dominant joint involvement patterns associate with better clinical outcomes in early rheumatoid arthritis
Rheumatology Meta-analysis
Hand-dominant joint involvement patterns associate with better clinical outcomes in early rheumatoid arthritis Joint Involvement Patterns May Influence Rheumatoid Arthritis Treatment Success
This individual patient data meta-analysis of 1250 patients evaluated the impact of joint involvement patterns on treatment response in earl…
New research suggests that where you experience joint pain in early rheumatoid arthritis may influence how well certain medications work.
Jul 3, 2026
Living systematic review finds low-certainty evidence that stopping csDMARDs before surgery may increase flare risk in inflammatory arthritis
Allergy & Immunology Sys. Review
Living systematic review finds low-certainty evidence that stopping csDMARDs before surgery may increase flare risk in inflammatory arthritis Stopping arthritis drugs before surgery may raise flare risk
This living systematic review evaluates perioperative management of conventional synthetic DMARDs in adults with rheumatoid arthritis, psori…
Low-certainty evidence suggests stopping certain arthritis drugs before surgery might increase the chance of a disease flare, but infection …
Cochrane May 20, 2026